American Society of Clinical Oncology

May 30 - June 03, 2025

Durvalumab
Rilvegostomig
AZD9793
Trastuzumab Deruxtecan
AZD5493
AZD0486
olaparib durvalumab
ceralasertib olaparib
Datopotamab Deruxtecan Rilvegostomig
Datopotamab Deruxtecan
Osimertinib
Savolitinib Osimertinib
Camizestrant
Selumetinib (Rare disease)

pdf

Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: A Phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC)

pdf

EMERALD-Y90: A Phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization

ppt

Event-free survival (EFS) in MATTERHORN: a randomized, Phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)

pdf

Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in patients (pts) with locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses

pdf

Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab in NIAGARA

ppt

Clinical and molecular characteristics of early progressors and long-term progression-free survivors from the phase 3 ADRIATIC trial of consolidation durvalumab vs placebo after concurrent chemoradiotherapy in limited-stage small-cell lung cancer

ppt

Associations of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the Phase 3 AEGEAN trial

pdf

Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2

pdf

Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in US patients with stage II/III non-small cell lung cancer

pdf

First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A

pdf

ARTEMIDE-Gastric01: A Phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC)

pdf

ARTEMIDE-Lung03: A Phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1

pdf

RHEA-1: First-in-human (FIH) study of AZD9793, a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC)

pdf

ARTEMIDE-Gastric01: A Phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC)

pdf

Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in HER2-low/-ultralow, hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)

pdf

Membrane specific HER2 expression by AI based quantitative scoring is predictive of efficacy of trastuzumab deruxtecan in biliary tract cancer (HERB trial): Exploratory analysis of a multicenter, single arm, Phase II trial

pdf

T-DXd + pertuzumab vs taxane + trastuzumab + pertuzumab (THP) for first-line treatment of patients with HER2+ advanced/mBC: interim results from DESTINY-Breast09 (DB-09)

pdf

Trastuzumab deruxtecan vs ramucirumab plus paclitaxel in second-line treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) unresectable and/or metastatic gastric cancer or gastroesophageal junction adenocarcinoma: Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study

pdf

TITANium: An open-label, global multicenter Phase 1/2 study of AZD5492, a first-in-class subcutaneous trispecific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies

pdf

SOUNDTRACK-E: A Phase 1/2 open-label multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies

pdf

Safety and efficacy of AZD0486, a CD19xCD3 T-cell Engager, in relapsed or refractory diffuse large B-cell lymphoma

pdf

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA

pdf

Ceralasertib (cerala) + olaparib (ola) in patients (pts) with homologous recombination repair (HRR)-deficient, platinum-sensitive relapsed (PSR) ovarian cancer (OC) after progression on prior PARP inhibitor (PARPi) treatment (tx)

pdf

First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5).

PPT

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).

ppt

Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA

pdf

Real-world (rw) study to identify disparities in outcomes for patients (pts) with early-stage resected NSCLC who received biomarker-targeted adjuvant treatment (BTRx)

ppt

Efficacy and CNS results from a randomized subset of the Phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO)

pdf

Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer: Phase 3, double-blind ctDNA-guided SERENA-6 trial

html

Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a phase 3, international, randomized, placebo-controlled study

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão